Regulatory Green Light for Controlled Trials of Light Therapy in Pain Management
PILLAR DIAGNOSTIC // WEEK 30
“With full alignment across pillars and no contradictory evidence, we assess transcranial photobiomodulation as low risk and suitable for phased human trials. Focus should shift to refining light wavelength, intensity and dosage protocols to maximize analgesic and anti‐inflammatory benefits while ensuring patient safety.”
Proposed action
Initiate controlled clinical studies under strict thermoregulatory monitoring, develop standardized treatment guidelines for light parameters, and implement real‐time safety surveillance to detect and manage any adverse thermal effects.
THE MECHANICS
Spread & delivery
—
THE MACHINE
Evidence & systems
Transcranial photobiomodulation uses noninvasive light to modulate brain activity, elevating scalp temperature by up to 3.76 °C and brain temperature by up to 0.57 °C, achieving penetration depths beyond 10 cm, with red light enhancing pain tolerance and green light reducing key inflammatory markers.
THE MAP
Policy & population
—
THE MOOD
Trust & behavior
—